Corporate Profile for Ergo Science Corporation, dated Nov. 9, 2001.Business Editors --(BUSINESS WIRE) The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services.
Published Date: Nov. 9, 2001
Company Name: Ergo Science Corporation
Address: 790 Turnpike Street, Suite 202
North Andover, MA 01845 USA
Main Telephone
Number: (978) 689-0333
Chief Executive
Officer: David R. Burt
Investor Relations
Contact: Lisa V. DeScenza
Business number: (978) 689-0333
E-mail address: ldescenza@ergo.com
Public Relations
Contact: Lisa V. DeScenza
Business number: (978) 689-0333
E-mail address: ldescenza@ergo.com
Trading Symbol/
Exchange: OTCBB: ERGO
From incorporation through March 2001, Ergo Latin, therefore; hence; because. ergo (air-go) conj. Latin for therefore, often used in legal writings. Its most famous use was in "Cogito, ergo sum:" "I think, therefore I am" principle by French philosopher Rene Descartes (1596-1650). Science was engaged in the development of ERGOSET(R) tablets for the treatment of type 2 diabetes type 2 diabetes n. See diabetes mellitus. . From incorporation through the second quarter of 1999, we also operated a pre-clinical research laboratory engaged in research relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc neuroendocrine neuroendocrine /neu·ro·en·do·crine/ (-en´do-krin) pertaining to neural and endocrine influence, and particularly to the interaction between the nervous and endocrine systems. neu·ro·en·do·crine adj. resetting therapy. During the second quarter of 1999, we sold substantially all of our laboratory equipment and terminated almost all of our employees engaged in preclinical activities in order to minimize our expenses while continuing to research the side effects Side effects Effects of a proposed project on other parts of the firm. of ERGOSET(R) and work with the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) to secure the approval of ERGOSET(R) for marketing. Although we have expended ex·pend tr.v. ex·pend·ed, ex·pend·ing, ex·pends 1. To lay out; spend: expending tax revenues on government operations. See Synonyms at spend. 2. considerable efforts since 1999 to persuade the FDA to approve ERGOSET(R), we have been unable to do so. In March 2001, Ergo Science decided that the next phase of the development of ERGOSET(R) would be better undertaken by a company that has more experience with human drug development and more resources for regulatory approval and marketing. Ergo Science is in the process of attempting to sell or license interests in ERGOSET(R) including intellectual property rights and other human drug related assets. In addition, Ergo Science is planning to transition to a new line of business through acquisition of an established business. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion